Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07661823

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428

BRIEF SUMMARY

A. "What is the purpose of this study?"

This study will test whether the "AI City Hall Project" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called "Microcities". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.

B. "What conditions does the study focus on?"

The study focuses on adults with:

* Autism spectrum disorders (Asperger's, autism, ADHD, ASD) * Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA/ecstasy, tobacco/nicotine) * Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders) * Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).

C. "What does the study involve?"

Eligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital "attitude inoculation" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.

**Who can participate?**

You may be able to join if you:

* Are an adult (18 years or older) * Have a diagnosis of one of the listed mental-health or addiction disorders * Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole/probation officer, judge) * Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.

Participants who are veterans, receive public assistance (e.g., VA disability, SSDI/SSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.

**Where is the study taking place?** The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.

**Who is sponsoring the study?** The study is sponsored by **Veterans Recovery Network Inc.**, a non-profit organization, in collaboration with **AI-119 Vulcan Project Research & Educational Technology Co. (PRETCO)** and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).

This summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Asperger's Disorder ADHD ADHD - Attention Deficit Disorder With Hyperactivity ASD Abstinence, Sex Addiction Disorders Alcohol Abuse/Dependence Alcohol Addiction Alcohol and Other Drug Use Disorders Alcohol and Other Substance Use Prevention Alcohol-Related Disorders Alcoholism Anger Problems Asperger Disorder Asperger Syndrome Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Autism Autism Disorder Autism Spectrum Disorder Autistic Disorder Behavior Behavior, Addictive Chemically-Induced Disorders Child Abuse, Sexual Child Development Disorders, Pervasive Cocaine Abuse Cocaine-Related Disorders Coitus Compulsive Behavior Compulsive Sexual Behavior Disorder Disruptive, Impulse Control, and Conduct Disorders Eating Behavior Disorders Gambling Gambling Addiction Gambling Disorder Gender Dysphoria Gender Dysphoria, Adult Genital Diseases Homeless and Low Incomes People, Refugees Homelessness Impulsive Behavior MDMA ('Ecstasy') Marijuana Abuse Marijuana Abuse and Dependence Marijuana Use Disorder Mental Disorders Narcissism Narcotic Addiction Narcotic-Related Disorders Neurodevelopmental Disorders Opiate Substitution Treatment Opioid Abuse (Disorder) Opioid Abuse and Addiction Opioid-Related Disorders Psychedelic Drug Dependence Psychedelic Effects in Healthy Volunteers Psychedelic Experiences Psychiatric Disorder Reliability and Validity Risk-Taking Sex Abuse Sex Behavior Sex Crimes Sex Disorder Sex Disorders Sexual Abstinence Sexual Behavior Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Sexual and Gender Disorders Smoking Smoking (Tobacco) Addiction Smoking Abstinence Smoking Among Youth Substance-Related Disorders Urogenital Diseases

Age range

17 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Administrative Office

Richmond, Virginia, 23219, United States

About this study

I. MEMBER PLATFORM OVERVIEW

The QAIAx platform operates a dual-framework infrastructure consisting of a commercial (US-based) quantum AI cloud-robotics layer and an RDT&E clinical research layer. Program participants are required to maintain active trainee, member, or intern status with the sponsoring organization, which includes a standard and premium monthly platform membership subscription, or QAIAx ecosystem site called a (QAIAx) 'microcity' (a sponsored member-organization community where RDT&E is held). This commercial fee provides standard access to a peer-to-peer access to virtual and physical 'holo-suites' via omni-AI humanoid, quantum AI agent (generative AI human-like avatar as a holographic/audio/visual bot controlled via remote LLM command point) or QAIAx microcity administrative via a cloud server sandbox for independent learning machine studies and P2P tech support. This membership constraint serves strictly as an organizational prerequisite for ecosystem access and is completely decoupled from the clinical trial protocol. No fee is charged to subjects for participating in the clinical research arms, or for accessing the patented experimental interventions (AI-119 / AI Wat '1498' utility patent series). For eligible applicants qualifying as low-income or homeless ADA/SSDI, military veterans, personnel of a state/federal government agency, or enrolled student of an accredited post-secondary school, the physical Omni-AI Microcity housing arms, standard platform subscription fees may qualify for a fully/partially sponsored or waived by the authorized non-governmental organization (NGO) for the duration of the trial monitoring period and full member subscription that aligns with an affiliated health services program or educational learning track program to ensure zero financial cost to the research subject.

II. PLATFORM & EQUIPMENT LEGAL AUTHORITIES.

Brief Summary of Data Sharing, Export Compliance, and Intellectual Property Restraints (Pursuant to the U.S. and EU laws)

This Cooperative Agreement acknowledges that the use of AI humanoids for U.S. Government-funded RDT&E is tightly governed by overlapping U.S. export control, intellectual property, and national security laws, with specific restrictions that also inform compliance under analogous EU frameworks.

  • Core Legal Shield - 28 U.S.C. § 1498 The Agreement explicitly invokes 28 U.S.C. § 1498, which channels any patent-infringement claim arising from Government-authorized use of AI humanoids exclusively to the U.S. Court of Federal Claims for monetary damages. This statutory shield protects both the Government and its contractors (including AI-119 Vulcan PRETCO) from injunctions or liability for using patented inventions with Government authorization or consent.
  • Section 1260H Firewall - Chinese Military Company Restriction Because the AI humanoid hardware is sourced from Beijing Noetix Robotics, whose sponsors include CATL - an entity listed under Section 1260H of the NDAA FY2021 as a "Chinese military company" - the Agreement imposes a complete data and technical-access bar. Noetix and all 1260H sponsors are absolutely restricted from receiving, viewing, or accessing any proprietary AI model weights, source code, or U.S. provisional patent specifications.
  • Export Control Classifications - ECCNs 3A090, 4A090, and 4E091 The technology is treated under the highest restrictive baseline of ECCNs 3A090 and 4A090 (advanced computing integrated circuits) and ECCN 4E091, which controls the "parameters" (model weights) of certain advanced closed-weight dual-use AI models. The Agreement mandates that all cloud hosting remain within the United States, and that no protected data or model weights be transmitted to servers in the People's Republic of China.
  • License Exception AIA - Ineligibility for Chinese Entities The Agreement acknowledges that Noetix, being headquartered in China, is ineligible for License Exception AIA (Artificial Intelligence Authorization) under Supplement No. 5 to Part 740 of the EAR. Consequently, any cross-border data access or technology transfer to Noetix or its sponsors would require a separate export license, which the Agreement explicitly precludes by denying them access to the firewalled API.
  • Intellectual Property Segregation - The Logical API Firewall All background intellectual property (including the pending USPTO provisional utility patent and all AI model weights) remains exclusively owned by PRETCO. A logical API firewall ensures that Noetix and its sponsors are strictly limited to receiving commercial off-the-shelf hardware components, with no access to source code, model weights, or system-level configurations. Access from international nodes is restricted to a firewalled API that transmits only structured inputs and non-sensitive telemetry.
  • EAR Fundamental Research Exclusion - Not Applicable Because the technology is governed by a § 1498 federal framework and the Parties have agreed that the sponsor may withhold publication (see 15 C.F.R. § 734.8), the standard EAR Fundamental Research Exclusion does not apply. All manuscripts, abstracts, or code fragments must be pre-cleared by an internal Export Compliance Board before any public release.
  • EU Law Consistency - AI Act & UNESCO Neuroethics The Agreement aligns with the EU AI Act by ensuring that any neurotechnology or biosignal-processing capabilities (e.g., "Quasi-Mind Ware" and "Attitude Inoculation") are classified as non-invasive wellness tools, not high-risk medical devices, and that the "Neural Exit" guarantee and hard-coded kill switches preserve user autonomy. It also respects the UNESCO Recommendation on the Ethics of Neurotechnology (2025) by mandating informed consent, transparency, and the protection of human dignity.
  • Survival of Restraints All data-restriction, export-compliance, and intellectual-property-segregation covenants survive any termination of the Agreement, including the potential expiration of the U.S.-China Agreement on Cooperation in Science and Technology in August 2029, and remain independently enforceable under U.S. and international law.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 17 to 99 years old.
  • Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).
  • Referral by a non-profit organization (e.g., 501c3, university, church).
  • Referral by a public agency (e.g., case manager, social worker, parole/probation/PTS officer, judge).

Exclusion criteria

  • Individuals under 17 or over 99 years of age.

Treatment and study plan

AI City Hall Project (AIhealth4u - Public Health Central)

Behavioral

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a). AI Public Health Central Microcity will focus on behavioral and psychiatric health for patients with various common mental health and addiction disorders, placed in monitored ecosystems with AI/AGI tools managing public administration resources under statistical surveys to determine to determine which fiscal viability, effectiveness and accuracy AI/AGI Health tools for mental health treatment (e.g., AI robotics; 'Quasi-Mind Ware' and Mental Health/Psychiatric Cyber-Medicine treatment applying AI Symbiosis, e.g., See 'Traum-to-Real' installation of generative AI memory into the human mind via attitude inoculation)

AI City Hall Project (QAIAx Microcity A - AI Public Health Central)

Behavioral

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64/074,526, 64/063,557, 63/903,181, 63/729,428: A quantum AI public health agency that provides free public health services to registered and sponsored visitors/occupants for RDT&E under 28 U.S. Code 1498 (classified as a PPA under 10 U.S. Code 129a)

Primary outcomes

  1. Vulcan QAIAx v4.0x (Beta ISAC) for AI-119 and AI Wat (1498) patent series for Private, Public, and Military sectors (Change from Baseline in Participant Lifestyle Efficiency, Behavioral Stability, & Sovereign Resource Allocation via Vulcan QAIAx v4.0)

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    This comprehensive description bridges the clinical parameters of the AI-119 Vulcan SOF Program (an AGI/AI Ecosystems RDT&E Program launched under the 119th U.S. Congress) and Veterans Recovery Network Program (VA-authorized program, est. 2020, Richmond VAMC) with the high-velocity public, private, and military administrative functions optimized by the AI-119 and AI Wat patent series under 28 U.S.C. § 1498 (Government Use of Patents), using a Omni-AI robotics among Holo-Suit, Quasi-Mind Ware (QM-Ware), Body-Ware, QAIA Humanoid (via "AI-Me" Hybrid AI Symbiote app). This primary outcome measures the definitive capacity of the Vulcan QAIAx v4.0x (Beta ISAC) autonomous platform to generate an efficient lifestyle, stabilize severe psychiatric and addiction disorders, and optimize administrative resource delivery across Private, Public, and Military sector frameworks. Utilizing a '90/10' hybrid workforce model (90% omni-AI Humanoid Workforce / 10% Human Auditor & Administrator oversight).

  2. Change from Baseline in Participant Lifestyle Efficiency and Behavioral Stability Index (via QAIAx 4.0x Core Analytics)

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    The primary outcome directly track the core clinical and lifestyle stabilization of the veterans residing in the monitored Microcity ecosystem, measuring the effectiveness of the advanced AI/AGI tools. Total duration (measured in months vs. the traditional multi-year trajectories) and accuracy rate of AI-driven legal/health document processing, error corrections, and intake evaluations managed by the 90% AI Humanoid Workforce under human auditor ethical oversight under 'Kikkeri doctrine' to 'hire a million to skill a billion.'

Secondary outcomes

  1. Economic Sustainability and Housing Retention Cost Index under the Omni-AI Microcity Model

    Time frame: Baseline enrollment, month 12, and month 24 (tracked monthly)

    Total financial variance and cost-mitigation rates achieved by housing occupants within the $100 to $2,000 per month extreme-affordability bracket (including digital device provisioning and logistics integration), evaluated against standard public healthcare and federal housing expenditure benchmarks.

Study contacts

Contact information is provided by the study sponsor or research team.

C Peterson

CONTACT

[email protected]

804-390-5037

RDTE Administrator

CONTACT

[email protected]

888-307-8380

Sponsors and collaborators

Lead sponsor

Veterans Recovery Network Inc.

Other

Collaborators

  • AI-119 Vulcan Project Research & Educational Technology Company (fka Henry Nanpei Academy Project)
  • Central Virginia VA Health Care System
  • U.S. Special Operations Command

Registry information

Official study title

QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App No(s). 64/105,164, 64/074,526, 64/063,557, 63/903,181, 63/729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors/Occupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)

Acronym: QAIAx

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 22, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.